Related Experiment Video

Updated: Jun 30, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.4K

Opportunity in Complexity: Harnessing Molecular Biomarkers and Liquid Biopsies for Personalized Sarcoma Care

Agnes Ewongwo1, Caressa Hui1, Everett J Moding2

  • 1Department of Radiation Oncology, Stanford University, Stanford, CA.

Seminars in Radiation Oncology
|March 20, 2024
PubMed

Insights

Molecular biomarkers are crucial for diagnosing and treating rare sarcomas. Emerging technologies like circulating tumor DNA analysis promise to further personalize sarcoma care and improve patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Sarcomas are rare and complex cancers presenting significant treatment challenges.
  • The diversity of sarcoma subtypes offers potential for personalized treatment strategies.
  • Understanding molecular drivers is key to improving sarcoma therapy.

Purpose of the Study:

  • To review the current landscape of molecular biomarkers in sarcoma.
  • To highlight the role of biomarkers in diagnosis, prognostication, and treatment selection.
  • To explore future opportunities and challenges for implementing novel biomarker technologies.

Main Methods:

  • Review of current literature on sarcoma molecular biomarkers.
  • Analysis of genetic, transcriptomic, and protein-based biomarkers.
  • Discussion of emerging technologies such as circulating tumor DNA (ctDNA).

Main Results:

  • Genetic, transcriptomic, and protein biomarkers are established tools in sarcoma management.
  • Biomarkers aid in accurate diagnosis, predicting patient prognosis, and guiding treatment choices.
  • Emerging biomarkers like ctDNA show potential for early detection and treatment monitoring.

Conclusions:

  • Molecular biomarkers are essential for personalized sarcoma care.
  • Advancements in biomarker technology will further refine early detection and treatment response monitoring.
  • Addressing implementation challenges is critical for realizing the full potential of novel biomarkers in sarcoma.

More Related Videos

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients08:25

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

11.0K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

11.8K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K